Doubling up to fight pain

July 13, 2016 by Anne Craig, Queen's University

Queen's University researcher Ian Gilron has uncovered a more effective way of treating fibromyalgia, a medical condition characterized by chronic widespread pain typically accompanied by fatigue, as well as sleep, mood and memory problems.

The results of the trial suggest that combining pregabalin, an anti-seizure drug, with duloxetine, an antidepressant, can safely improve outcomes in fibromyalgia, including not only pain relief, but also physical function and overall quality of life. Until now, these drugs have been proven, individually, to treat fibromyalgia pain.

"Previous evidence supports added benefits with some drug combinations in fibromyalgia," says, Dr. Gilron (Anesthesiology, Biomedical Sciences). "We are very excited to present the first evidence demonstrating superiority of a duloxetine-pregabalin combination over either drug alone."

Fibromyalgia was initially thought to be a musculoskeletal disorder. Research now suggests it's a disorder of the central nervous system - the brain and spinal cord. Researchers believe that fibromyalgia amplifies painful sensations by affecting the level and activity of brain chemicals responsible for processing .

"The condition affects about 1.5 to 5 per cent of Canadians - more than twice as many women as men. It can have a devastating on the lives of patients and their families," explains Dr. Gilron. "Current treatments for fibromyalgia are either ineffective or intolerable for many patients."

This study is the latest in a series of clinical trials - funded by the Canadian Institutes of Health Research (CIHR) - that Dr. Gilron and his colleagues have conducted on combination therapies for conditions. By identifying and studying promising , their research is showing how physicians can make the best use of current treatments available to patients.

"The value of such combination approaches is they typically involve drugs that have been extensively studied and are well known to health-care providers," says Dr. Gilron.

This new research was published in the journal Pain.

Dr. Gilron and his research team at Queen's are members of the SPOR Network on Chronic Pain. The national network, funded under Canada's Strategy for Patient-Oriented Research, directs new research, trains researchers and clinicians, increases access to care for , and speeds up the translation of the most recent research into practice.

Explore further: Combining nortriptyline and morphine provides better pain relief than using either drug alone

Related Stories

Combining nortriptyline and morphine provides better pain relief than using either drug alone

April 7, 2015
The combination of two well-known drugs will have unprecedented effects on pain management, says new research from Queen's.

Fibromyalgia and the role of brain connectivity in pain inhibition

October 1, 2014
The cause of fibromyalgia, a chronic pain syndrome is not known. However, the results of a new study that compares brain activity in individuals with and without fibromyalgia indicate that decreased connectivity between pain-related ...

Brain imaging reveals dynamic changes caused by pain medicines

November 19, 2013
A study in the December issue of Anesthesiology suggests a role for brain imaging in the assessment and potential treatment of chronic pain.

IV lidocaine has no meaningful impact in fibromyalgia

June 20, 2016
(HealthDay)—For patients with fibromyalgia, use of intravenous lidocaine has no meaningful impact, according to a study published online June 16 in the International Journal of Rheumatic Diseases.

Fatigue not a factor in fibromyalgia pain, study says

April 26, 2012
(HealthDay) -- Poor sleep is not a significant predictor of pain intensity and duration in patients with fibromyalgia, a new study says.

Recommended for you

Researchers define possible molecular pathway for neurodegeneration in prion diseases

September 21, 2018
A new study has shed light on the mechanisms underlying the progression of prion diseases and identified a potential target for treatment.

Pre-clinical success for a universal flu vaccine offers hope for third generation approach

September 21, 2018
Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Communications.

A new approach to developing a vaccine against vivax malaria

September 21, 2018
A novel study reports an innovative approach for developing a vaccine against Plasmodium vivax, the most prevalent human malaria parasite outside sub-Saharan Africa. The study led by Hernando A. del Portillo and Carmen Fernandez-Becerra, ...

Fighting a deadly parasite: Scientists devise a method to store Cryptosporidium, aiding vaccine research efforts

September 21, 2018
In May, just before one of the hottest summers on record, the U.S. Centers for Disease Control and Prevention issued a warning about diseases lurking in recreational water facilities like swimming pools and water playgrounds. ...

Affordable Care Act: Study finds surprising gaps in HIV care providers' knowledge

September 20, 2018
A new study has revealed surprising gaps in some HIV medical providers' knowledge of the Affordable Care Act, with more than a quarter of providers surveyed unable to say whether their state had expanded Medicaid.

Preventing a dengue outbreak at the 2020 Summer Olympics

September 20, 2018
In 2014, a dengue outbreak unexpectedly occurred in Tokyo. What does that mean for the 2020 summer Olympics and Paralympics being held in the city? Researchers report this week in PLOS Neglected Tropical Diseases that new ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.